Skip to main content
. 2004 Jul;48(7):2431–2436. doi: 10.1128/AAC.48.7.2431-2436.2004

TABLE 4.

Contribution of resistance to individual antimicrobial agents to MDR phenotypes in clinical isolates of P. aeruginosa collected from 1999 to 2002

Patient group, specimen source, or collection yra % Isolates (no.)b that had an MDR phenotype % of MDR isolates resistant to:
Ceftazidime Piperacillin-tazobactam Ticarcillin-clavulanate Gentamicin Ciprofloxacin Imipenem Tobramycin
Patient type
    Non-ICU 25.4 (6,526) 52.8 47.7 83.3 58.6 77.9 44.7 45.4
    ICU 29.5 (1,795) 59.7 48.0 85.6 60.3 71.5 55.9 50.0
    OP 19.4 (3,103) 41.7 39.2 66.1 74.1 71.2 36.2 57.1
    NH 29.9 (775) 45.3 34.3 89.3 54.8 79.7 26.3 44.2
    All 24.2 (12,199) 50.5 44.7 79.6 62.6 75.4 43.0 49.0
Patient age (yr)
    ≥18-39 29.0 (2,463) 49.6 42.5 68.5 76.0 71.9 42.1 53.2
    40-49 25.2 (1,290) 52.9 46.7 80.5 58.5 74.8 50.8 46.4
    50-59 27.2 (1,771) 55.0 49.5 84.3 58.9 78.3 45.2 50.0
    60-69 26.6 (1,817) 54.2 49.9 86.2 54.0 76.8 48.9 43.0
    >70 21.5 (3,389) 50.2 44.4 83.9 57.2 81.7 40.2 47.5
    All 25.0 (10,730) 51.9 46.0 80.4 61.4 77.2 44.2 48.3
Specimen source
    Blood 23.4 (443) 54.6 47.2 82.4 65.5 78.3 55.1 56.2
    LRT 31.3 (6,264) 51.9 46.3 77.9 61.6 70.4 45.4 46.4
    URT 5.8 (80) 43.7 40.0 55.0 70.0 62.5 47.5 46.3
    Wound 20.7 (2,434) 56.8 51.4 84.9 56.3 75.5 43.2 46.0
    All 26.0 (9,221) 53.2 47.6 79.8 60.4 72.1 45.3 46.7
Yr sample collected
    1999 22.7 (1,462) 55.1 55.9 78.5 60.3 67.0 40.9 43.4
    2000 24.9 (2,536) 51.6 50.3 76.5 69.8 71.1 46.2 53.1
    2001 26.2 (4,366) 48.5 40.8 78.8 64.7 77.1 41.4 52.7
    2002 24.5 (4,753) 47.2 39.5 82.0 59.6 80.8 46.0 47.6
    All 24.9 (13,117) 49.4 43.9 79.5 63.4 76.2 43.9 49.9
a

Abbreviations: OP, outpatients; NH, nursing home; LRT and URT, lower and upper respiratory tract, respectively.

b

Total percentage and number of isolates associated with MDR (resistance to ≥3 of the 10 antimicrobial agents).